PRPO | Precipio, Inc. Stock Overview

(Stock Exchange: NASDAQ)

Day's Range	5.22 - 5.46
52 Week Range	4.31 - 7.30
Beta	1.36
Implied Volatility	553.13%
IV Rank	N/A
Day's Volume	2,597
Average Volume	7,093
Shares Outstanding	1,482,330
Market Cap	7,811,879
Sector	Healthcare
Industry	Medical - Diagnostics & Research
IPO Date	2017-06-30

Valuation
Profitability
Growth
Health
P/E Ratio	-2.91
Forward P/E Ratio	N/A
EPS	-1.81
1YR Price Target	N/A
Dividend Yield	N/A
Dividend Per Share	N/A
Dividend ExDate	N/A
Dividend PayDate	N/A
Employees	51
Country	USA
Website	PRPO

Precipio, Inc., a healthcare solutions company, provides diagnostic products, reagents, and services in the United States. It provides diagnostic blood cancer testing services. The company offers IV-Cell, a proprietary cell culture media that enables simultaneous culturing of four hematopoietic cell lineages; HemeScreen, a suite of robust genetic diagnostic panels; ICE-COLD PCR, a proprietary and patented specimen technology that increases the sensitivity of molecular based tests; and COVID-19 antibody tests. It sells ICE-COLD-PCR technology kits to bio-pharma customers. Precipio, Inc. has collaborations with academic institutions specializing in cancer research, diagnostics, and treatment. The company is based in New Haven, Connecticut.

PRPO's peers: OCX, PRPH, BDSX, SERA, APDN, OLK, CDNA, CSTL, TWST, NTRA, HTGM, GTH, BIAF, PMD, GENE, MDXH, STRR, XGN, BNR, LMDX

*Chart delayed

Analyzing fundamentals for PRPO we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is unacceptably poor, Growth is desperately bad and Health is frighteningly weak. For more detailed analysis please see PRPO Fundamentals page.

Watching at PRPO technicals we can see that long-term trend is bearish, the same as bearish middle-term trend, as well as bearish short-term trend. More technicals details can be found on PRPO Technicals page.